| Fiscal Year End | Company Status | Exempt Flag |
| September 30 | Delist | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 6/Jan/2009 | 1/Nov/2020 | Canada | British Columbia | |
|
|
| Exchange Filing Office |
| Location |
| (not available) |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Biotechnology Research &/or Development
| (not available)
|
|
| *Biotechnology Research &/or Development
| News Release March 6, 2014-ESSA Pharma Inc. is a development-stage pharmaceutical company focused on a proprietary small molecule compound named EPI-506 as a treatment for advanced prostate cancer. EPI-506 was designed to block a novel target on the androgen receptor, the N-terminal domain. Inhibition of the N-terminal domain of the androgen receptor has the potential to block tumor growth after current hormone-therapy drugs have failed. That potential has been demonstrated by ESSA in several well-accepted in vitro and in vivo studies showing that EPI-506 inhibits tumor growth in those models. The target patient population for EPI-506 - metastatic castration resistant prostate cancer patients who have failed current hormone therapies - represents the greatest unmet medical need in this therapeutic area.
|
| Secondary
| *Biotechnology Research &/or Development
| News Release March 6, 2014-ESSA Pharma Inc. is a development-stage pharmaceutical company focused on a proprietary small molecule compound named EPI-506 as a treatment for advanced prostate cancer. EPI-506 was designed to block a novel target on the androgen receptor, the N-terminal domain. Inhibition of the N-terminal domain of the androgen receptor has the potential to block tumor growth after current hormone-therapy drugs have failed. That potential has been demonstrated by ESSA in several well-accepted in vitro and in vivo studies showing that EPI-506 inhibits tumor growth in those models. The target patient population for EPI-506 - metastatic castration resistant prostate cancer patients who have failed current hormone therapies - represents the greatest unmet medical need in this therapeutic area.
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *EPI | *ESSA Pharma Inc. | TSX Venture | DELIST |
| *EPI | *Essa Pharm Old | TSX Venture | DELIST |
| *EPI | *Essa Pharma Inc. | TSX Venture | DELIST |
|
|
| Name History | From | To |
| *ESSA Pharma Inc. | 31/Jul/2017 | 1/Nov/2020 |
| *Essa Pharma Inc. | 24/Sep/2014 | 27/Jul/2015 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
